Ontology highlight
ABSTRACT: Introduction
Recombinant human luteinizing hormone (r-hLH) is used in a fixed-ratio combination with recombinant human follicle-stimulating hormone (r-hFSH) for the stimulation of follicular development.Objective
The objective of this article was to conduct a review of safety data to evaluate the risks of r-hFSH/r-hLH treatment.Methods
Data were retrieved from the Global Safety Database (Merck KGaA, Darmstadt, Germany) including reports from healthcare professionals, patients, health authorities, clinical trials, non-interventional studies, and the literature. Reports of important risks (identified and potential) as per the risk management plan applicable at the time of data retrieval were obtained up to December 2017. The estimated patient exposure to r-hFSH/r-hLH
SUBMITTER: Abramova N
PROVIDER: S-EPMC6426819 | biostudies-literature | 2019 Mar
REPOSITORIES: biostudies-literature